1. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
- Author
-
Pongas,Georgios and Cheson,Bruce
- Subjects
Targets and Therapy [Blood and Lymphatic Cancer] - Abstract
Georgios Pongas,1 Bruce Cheson2 1Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Lymphoma Research Foundation, North Bethesda, MD, USACorrespondence: Bruce Cheson Email bdcheson@gmail.comAbstract: Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptorâT-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.Keywords: bispecific antibodies, BsAbs, chimeric antigen receptor â T cell therapies, CAR-T, lenalidomide
- Published
- 2021